ADAG
Bullish signal
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Supports a bullish reading. Open-market purchases outweigh sales
- Congress Unavailable or mixed. No purchase disclosures in the stored window
- Financial indicators Unavailable or mixed. Current ratio 3.07 · operating margin -279% — readings disagree
- Narrative Pulls against a bullish reading. Stored narrative reading is in the bearish band
- Timing Supports a bullish reading. Interesting trend — weekly bias up
ACHAT TOTAL: 23245 titres (~84764 USD)
- Insiders
- Luo Peter
- Total bought
-
$84,764
Avg buy (VWAP, 90d window) $3.43 vs last close $3.23 (-5.9%)
- Total sold
-
—
Avg sell (VWAP, 90d window) —
- Last activity
- 2026-08-05
- Liquidity
- Illiquid $657,479/day · 20d vol
- Last synced
-
2026-09-22 21:10:02
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
Market snapshot
Signal
Bullish signalScored 2026-09-20
ADAG presents a deeply distressed financial profile with a liquidity score of 45 and a fundamentals trend score of only 25, reflecting persistent cash burn, negative operating margins, and no clear path to commercial…
The first sentence of the analysis written for ADAG on 2026-09-20 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 100.0% | -797.5% | 100.0% | 100.0% | 100.0% | |
| Ebit Margin | -227.4% | -31578.0% | -89.2% | -848.2% | -698.9% | |
| Ebitda Margin | -219.7% | -30680.5% | -82.5% | -832.8% | -687.8% | |
| Operating Profit Margin | -279.5% | -34835.4% | -131.0% | -903.1% | -711.2% | |
| Pretax Profit Margin | -233.4% | -32403.5% | -95.3% | -855.6% | -702.5% | |
| Continuous Operations Profit Margin | -229.6% | -32386.4% | -104.6% | -860.6% | -719.2% | |
| Net Profit Margin | -229.6% | -32386.4% | -104.6% | -860.6% | -719.2% | |
| Bottom Line Profit Margin | -229.6% | -32386.4% | -104.6% | -860.6% | -719.5% | |
| Current Ratio | 3.074 | 2.299 | 3.606 | 2.711 | 6.235 | |
| Quick Ratio | 3.074 | 2.299 | 3.606 | 2.711 | 6.235 | |
| Solvency Ratio | -0.397 | -0.839 | -0.393 | -1.133 | -2.187 | |
| Cash Ratio | 2.961 | 2.231 | 3.495 | 2.610 | 5.848 | |
| Price To Earnings Ratio | -4.086 | -2.095 | -3.509 | -0.573 | -3.527 | |
| Price To Earnings Growth Ratio | 0.080 | -0.029 | 0.046 | -0.524 | -0.012 | |
| Forward Price To Earnings Growth Ratio | 0.080 | -0.029 | 0.046 | -0.524 | -0.012 | |
| Price To Earnings Diluted Ratio | -4.086 | -2.095 | -3.591 | -0.573 | -3.527 | |
| Price To Earnings Diluted Growth Ratio | 0.080 | -0.027 | 0.047 | -0.524 | -0.012 | |
| Price To Book Ratio | 2.019 | 1.419 | 0.948 | 0.552 | 1.650 | |
| Price To Sales Ratio | 9.304 | 694.627 | 3.692 | 4.940 | 25.390 | |
| Price To Free Cash Flow Ratio | -4.553 | -2.411 | -2.343 | -0.931 | -5.626 | |
| Price To Operating Cash Flow Ratio | -4.558 | -2.414 | -2.350 | -0.944 | -5.951 | |
| Debt To Assets Ratio | 0.080 | 0.207 | 0.193 | 0.184 | 0.040 | |
| Debt To Equity Ratio | 0.177 | 0.366 | 0.316 | 0.337 | 0.048 | |
| Debt To Capital Ratio | 0.151 | 0.268 | 0.240 | 0.252 | 0.046 | |
| Long Term Debt To Capital Ratio | 0.031 | 0.008 | 0.161 | 0.145 | 0.019 | |
| Financial Leverage Ratio | 2.214 | 1.767 | 1.640 | 1.834 | 1.210 | |
| Working Capital Turnover Ratio | 0.151 | 0.002 | 0.206 | 0.074 | 0.093 | |
| Operating Cash Flow Ratio | -0.622 | -0.778 | -0.905 | -0.883 | -1.456 | |
| Operating Cash Flow Sales Ratio | -2.041 | -287.789 | -1.571 | -5.231 | -4.267 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.001 | 1.001 | 1.003 | 1.014 | 1.058 | |
| Debt Service Coverage Ratio | -3.042 | -1.697 | -1.751 | -5.439 | -14.747 | |
| Interest Coverage Ratio | -46.290 | -42.203 | -21.411 | -121.041 | -198.933 | |
| Short Term Operating Cash Flow Coverage Ratio | -3.144 | -1.669 | -3.389 | -3.569 | -9.653 | |
| Operating Cash Flow Coverage Ratio | -2.500 | -1.606 | -1.276 | -1.738 | -5.797 | |
| Capital Expenditure Coverage Ratio | -918.164 | -884.484 | -334.716 | -70.356 | -17.297 | |
| Dividend Paid And Capex Coverage Ratio | -918.164 | -884.484 | -334.716 | -70.356 | -17.297 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -0.185 | -0.158 | 1.389 | 0.903 | -1.307 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 100.0% | ▲897.5% | ▲179.5% |
| Ebit Margin | -227.4% | ▲31350.6% | ▲6460.9% |
| Ebitda Margin | -219.7% | ▲30460.8% | ▲6281.0% |
| Operating Profit Margin | -279.5% | ▲34555.9% | ▲7092.6% |
| Pretax Profit Margin | -233.4% | ▲32170.0% | ▲6624.6% |
| Continuous Operations Profit Margin | -229.6% | ▲32156.9% | ▲6630.5% |
| Net Profit Margin | -229.6% | ▲32156.9% | ▲6630.5% |
| Bottom Line Profit Margin | -229.6% | ▲32156.9% | ▲6630.6% |
| Current Ratio | 3.074 | ▲0.775 | ▼-0.511 |
| Quick Ratio | 3.074 | ▲0.775 | ▼-0.511 |
| Solvency Ratio | -0.397 | ▲0.442 | ▲0.593 |
| Cash Ratio | 2.961 | ▲0.730 | ▼-0.468 |
| Price To Earnings Ratio | -4.087 | ▼-1.992 | ▼-1.328 |
| Price To Earnings Growth Ratio | 0.080 | ▲0.108 | ▲0.168 |
| Forward Price To Earnings Growth Ratio | 0.080 | ▲0.108 | ▲0.168 |
| Price To Earnings Diluted Ratio | -4.087 | ▼-1.992 | ▼-1.312 |
| Price To Earnings Diluted Growth Ratio | 0.080 | ▲0.107 | ▲0.167 |
| Price To Book Ratio | 2.019 | ▲0.600 | ▲0.701 |
| Price To Sales Ratio | 9.305 | ▼-685.322 | ▼-138.286 |
| Price To Free Cash Flow Ratio | -4.553 | ▼-2.143 | ▼-1.381 |
| Price To Operating Cash Flow Ratio | -4.559 | ▼-2.145 | ▼-1.315 |
| Debt To Assets Ratio | 0.080 | ▼-0.127 | ▼-0.061 |
| Debt To Equity Ratio | 0.177 | ▼-0.189 | ▼-0.072 |
| Debt To Capital Ratio | 0.150 | ▼-0.117 | ▼-0.041 |
| Long Term Debt To Capital Ratio | 0.031 | ▲0.023 | ▼-0.042 |
| Financial Leverage Ratio | 2.214 | ▲0.447 | ▲0.481 |
| Working Capital Turnover Ratio | 0.151 | ▲0.149 | ▲0.046 |
| Operating Cash Flow Ratio | -0.622 | ▲0.156 | ▲0.306 |
| Operating Cash Flow Sales Ratio | -2.041 | ▲285.748 | ▲58.139 |
| Free Cash Flow Operating Cash Flow Ratio | 1.001 | -0.000 | ▼-0.014 |
| Debt Service Coverage Ratio | -3.042 | ▼-1.345 | ▲2.293 |
| Interest Coverage Ratio | -46.290 | ▼-4.087 | ▲39.686 |
| Short Term Operating Cash Flow Coverage Ratio | -3.144 | ▼-1.475 | ▲1.141 |
| Operating Cash Flow Coverage Ratio | -2.500 | ▼-0.894 | ▲0.083 |
| Capital Expenditure Coverage Ratio | -918.164 | ▼-33.680 | ▼-473.161 |
| Dividend Paid And Capex Coverage Ratio | -918.164 | ▼-33.680 | ▼-473.161 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -0.185 | ▼-0.027 | ▼-0.313 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $71.4M | $71.7M | $66.9M | $45.9M | $258.4M | |
| Enterprise value | $3.1M | $5.0M | -$20.8M | -$69.9M | $91.5M | |
| EV / Sales | 0.41x | 48.33x | -1.15x | -7.52x | 8.99x | |
| EV / Op. cash flow | -0.20x | -0.17x | 0.73x | 1.44x | -2.11x | |
| EV / Free cash flow | -0.20x | -0.17x | 0.73x | 1.42x | -1.99x | |
| EV / EBITDA | -0.18x | -0.16x | 1.39x | 0.90x | -1.31x | |
| Net debt / EBITDA | 4.05x | 2.11x | 5.86x | 1.50x | 2.38x | |
| Current ratio | 3.07x | 2.30x | 3.61x | 2.71x | 6.24x | |
| Income quality | 0.89x | 0.89x | 1.50x | 0.61x | 0.59x | |
| Graham net-net | $1 | $1 | $2 | $2 | $5 | |
| Tax burden | 98.3% | 99.9% | 109.8% | 100.6% | 102.4% | |
| Interest burden | 102.7% | 102.6% | 106.9% | 100.9% | 100.5% | |
| Working capital | $52.2M | $49.6M | $82.0M | $94.2M | $156.1M | |
| Invested capital | $53.1M | $51.0M | $84.2M | $97.2M | $159.6M | |
| Return on assets | -22.5% | -37.4% | -16.4% | -52.5% | -38.6% | |
| Operating ROA | -25.6% | -35.1% | -17.7% | -49.1% | -52.9% | |
| Return on tangible assets | -22.5% | -37.4% | -16.4% | -52.5% | -38.6% | |
| Return on equity | -49.8% | -66.2% | -26.9% | -96.2% | -46.7% | |
| Return on invested capital | -36.2% | -52.0% | -25.5% | -75.5% | -44.1% | |
| Return on capital employed | -40.4% | -70.4% | -28.1% | -86.2% | -45.3% | |
| Earnings yield | -24.7% | -46.6% | -28.3% | -174.2% | -28.3% | |
| Free cash flow yield | -22.0% | -41.5% | -42.7% | -107.4% | -17.8% | |
| Capex / Op. cash flow | -0.1% | -0.1% | -0.3% | -1.4% | -5.8% | |
| Capex / Depreciation | 2.9% | 3.6% | 7.0% | 47.7% | 223.1% | |
| Capex / Sales | 0.2% | 32.5% | 0.5% | 7.4% | 24.7% | |
| SG&A / Sales | 92.2% | 7047.5% | 47.9% | 127.8% | 141.9% | |
| R&D / Sales | 287.2% | 27887.9% | 202.3% | 875.3% | 669.3% | |
| Stock comp / Sales | 48.8% | 4757.2% | 40.1% | 113.2% | 183.6% | |
| Intangibles / Total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Days sales outstanding | 1d | 29d | 4d | 24d | 269d | |
| Days payables outstanding | 0d | 0d | 0d | 0d | 0d | |
| Operating cycle | 1d | 29d | 4d | 24d | 269d | |
| Cash conversion cycle | 1d | 29d | 4d | 24d | 269d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▼-0.4%EV / Sales ▼-99.2%EV / EBITDA ▼-17.3%EV / Op. cash flow ▼-0.031Earnings yield ▲+0.220
Profitability
Return on equity ▲+0.163Return on assets ▲+0.149Return on invested capital ▲+0.158Return on capital employed ▲+0.300Operating ROA ▲+0.095Income quality ▲+0.001Tax burden ▼-0.016
Efficiency
Days sales outstanding ▼-28.561Days payables outstanding n/aOperating cycle ▼-28.561Cash conversion cycle ▼-28.561Capex / Sales ▼-0.323R&D / Sales ▼-276.006
Balance-sheet strength
Current ratio ▲+0.775Net debt / EBITDA ▲+1.943Working capital ▲+2610002.000Invested capital ▲+2063877.000Intangibles / Total assets n/a
Change over 5 years
Valuation
Market cap ▼-72.4%EV / Sales ▼-95.5%EV / EBITDA ▲+85.9%EV / Op. cash flow ▲+1.908Earnings yield ▲+0.037
Profitability
Return on equity ▼-0.031Return on assets ▲+0.161Return on invested capital ▲+0.078Return on capital employed ▲+0.049Operating ROA ▲+0.273Income quality ▲+0.296Tax burden ▼-0.040
Efficiency
Days sales outstanding ▼-268.449Days payables outstanding n/aOperating cycle ▼-268.449Cash conversion cycle ▼-268.449Capex / Sales ▼-0.244R&D / Sales ▼-3.820
Balance-sheet strength
Current ratio ▼-3.162Net debt / EBITDA ▲+1.665Working capital ▼-103928851.000Invested capital ▼-106553559.000Intangibles / Total assets n/a
Employee count
Peer market caps
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Recent news
- 2026-06-05 Adagene (ADAG) Upgraded to Buy: Here''s What You Should Know Adagene (ADAG) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
- 2026-06-02 Are Medical Stocks Lagging Adagene (ADAG) This Year? Here is how Adagene Inc. Sponsored ADR (ADAG) and Contineum Therapeutics, Inc. (CTNM) have performed compared to their sector so far this year.
- 2026-05-19 Adagene Spotlights ADG126 Strategy as Masked CTLA-4 Trial Advances in Colorectal Cancer Adagene NASDAQ: ADAG Chief Strategy Officer Mickael Chane-Du outlined the company''s clinical strategy for its lead antibody program, ADG126, during a discussion with Stifel senior biotech analyst Stephen Willey, emphasizing the company''s focus on improving the therapeutic index of CTLA-4 inhibition through its proprietary masking technology.
- 2026-05-12 Adagene to Participate in Two Upcoming Investor Conferences SAN DIEGO and SUZHOU, China, May 12, 2026 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene or the Company”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced that senior management will participate in one-on-one investor meetings and a fireside chat at the Stifel Annual Virtual Oncology Event on May 19-20, 2026 and one-on-one investor meetings at the Jefferies LLC Global Healthcare Conference being held June 2-4, 2026 in New York, NY.